Professional Documents
Culture Documents
Received 30 January 2015; revised 23 March 2015; accepted 23 April 2015; online publish-ahead-of-print 28 May 2015
See page 1952 for the editorial comment on this article (doi:10.1093/eurheartj/ehv272)
Aims The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all-cause mortality
compared with enalapril in patients with chronic heart failure in the prospective comparison of ARNI with an Angio-
tensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARA-
DIGM-HF) trial. To more completely understand the components of this mortality benefit, we examined the effect of
LCZ696 on mode of death.
.....................................................................................................................................................................................
Methods PARADIGM-HF was a prospective, double-blind, randomized trial in 8399 patients with chronic heart failure,
and results New York Heart Association Class II – IV symptoms, and left ventricular ejection fraction ≤40% receiving guideline-
recommended medical therapy and followed for a median of 27 months. Mode of death was adjudicated by a blinded
clinical endpoints committee. The majority of deaths were cardiovascular (80.9%), and the risk of cardiovascular death
was significantly reduced by treatment with LCZ (hazard ratio, HR 0.80, 95% CI 0.72–0.89, P , 0.001). Among cardio-
vascular deaths, both sudden cardiac death (HR 0.80, 95% CI 0.68 –0.94, P ¼ 0.008) and death due to worsening heart
failure (HR 0.79, 95% CI 0.64 – 0.98, P ¼ 0.034) were reduced by treatment with LCZ696 compared with enalapril.
Deaths attributed to other cardiovascular causes, including myocardial infarction and stroke, were infrequent and dis-
tributed evenly between treatment groups, as were non-cardiovascular deaths.
.....................................................................................................................................................................................
Conclusions LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure,
which accounted for the majority of cardiovascular deaths.
.....................................................................................................................................................................................
Clinical Trial https://clinicaltrials.gov/, NCT01035255.
Registration
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Heart failure † Clinical trial † Pharmacotherapy † Neprilysin inhibition † Angiotensin-receptor blocker † Mortality
Despite significant therapeutic advances, patients with chronic angiotensin-converting enzyme (ACE) inhibitors, angiotensin-
heart failure remain at high risk for heart failure progression and receptor blockers (ARBs), b-adrenergic-receptor blockers, and
death.1,2 Among patients with heart failure and reduced ejection aldosterone antagonists influence the incidence of sudden cardiac
fraction (HF-REF), therapies that improve mortality, including death and death from progressive heart failure, but not the
incidence of death from myocardial infarction (MI), stroke, or sub-classified according to whether patients had been last seen alive
non-cardiovascular causes.3 – 11 LCZ696 is a first-in-class angioten- within 1 h or between 1 and 24 h. Apparent sudden deaths in patients
sin-receptor-neprilysin inhibitor (ARNI) comprised of the neprilysin who were last seen .24 h prior to death were separately categorized as
inhibitor prodrug sacubitril and the ARB valsartan.12,13 The Pro- presumed sudden death. Death due to MI was assigned for patients dy-
ing within 14 days of a clinical MI, those with autopsy evidence of recent
spective Comparison of ARNI with an ACE-Inhibitor to Determine
infarction, or those with an abrupt death associated with ECG, biomark-
Impact on Global Mortality and Morbidity in Heart Failure trial
er, or imaging evidence of acute myocardial injury. Death from worsen-
(PARADIGM-HF) randomized patients with chronic HF-REF to
ing heart failure was defined as death in the context of clinically
LCZ696 or enalapril, and demonstrated that treatment with worsening symptoms and/or signs of heart failure with no other appar-
LCZ696 reduced the composite primary outcome of cardiovascular ent cause, death as a consequence of a surgical procedure to treat heart
death or heart failure hospitalization, as well as cardiovascular death failure, or death after referral to hospice for heart failure. Death due to
and all-cause mortality.14 To more completely understand the mor- stroke was assigned if deaths occurred as a sequela of a stroke defined
tality reduction associated with LCZ696, we assessed the effect of by clinical or imaging criteria. Death within 14 days of a cardiovascular
LCZ696 compared with enalapril on the mode of death in procedure (other than a surgical procedure to treat heart failure) was
PARADIGM-HF. attributed to complications of that procedure, unless another cause
was readily apparent. Pulmonary embolism death was assigned only
for deaths occurring as a direct result of a documented pulmonary em-
Methods bolism. Remaining deaths that could be classified were presumed to be
unspecified cardiovascular deaths unless a specific non-cardiovascular
SBP, systolic blood pressure; BMI, body mass index; HF, heart failure; CMP, cardiomyopathy; NYHA, New York Heart Association; MI, myocardial infarction; ACE-I,
angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy; LVEF, left
ventricular ejection fraction.
the LCZ696 group and 693 (16.5%) in the enalapril group (HR for deaths, 0.8% of patients) could not be assigned to a clear cardiovas-
death from cardiovascular causes with LCZ696 vs. enalapril 0.80; cular or non-cardiovascular cause, and were distributed similarly
95% CI 0.72 – 0.89; P , 0.001). An additional 229 deaths (14.8% between the treatment groups. Regional variations in the proportion
of deaths) were assigned to non-cardiovascular causes, including of cardiovascular and non-cardiovascular deaths and the mode of
120 deaths (2.8% of total patients) in the LCZ696 group and 109 cardiovascular death are summarized in Supplementary material
deaths (2.5% of total patients) in the enalapril group. Non- online, Table S1.
cardiovascular deaths did not differ by randomized treatment The incidence of cause-specific death, according to treatment as-
groups (HR 1.07 for non-CV death, LCZ696 vs. enalapril, 95% CI signment is summarized in Table 3. The majority of cardiovascular
0.85 – 1.34, P ¼ 0.59). The remaining 66 unknown deaths (4.3% of deaths were categorized as sudden (44.8%) or heart failure related
Mode of death in PARADIGM-HF 1993
Characteristic Death due to HF Sudden Death Other CV deatha Non-CV Death P (all categories)
(N 5 331) (N 5 561) (N 5 359) (N 5 295)
...............................................................................................................................................................................
Age (years) 65.9 + 12.5 63.1 + 12.0 66.6 + 11.7 68.1 + 11.8 ,0.001
Sex: female, n (%) 56 (16.9%) 94 (16.8%) 68 (18.9%) 47 (15.9%) 0.75
...............................................................................................................................................................................
Race or ethnic group ,0.001
White 211 (63.7%) 314 (56.0%) 237 (66.0%) 222 (75.3%)
Black 15 (4.5%) 36 (6.4%) 15 (4.2%) 13 (4.4%)
Asian 57 (17.2%) 152 (27.1%) 52 (14.5%) 27 (9.2%)
Other 48 (14.5%) 59 (10.5%) 55 (15.3%) 33 (11.2%)
SBP (mmHg) 117 + 14 121 + 15 124 + 16 122 + 16 ,0.001
Heart rate (bpm) 74 + 13 73 + 12 73 + 12 74 + 14 0.59
BMI (kg/m2) 27.5 + 5.4 27.4 + 5.6 28.1 + 5.6 27.8 + 5.7 0.28
Creatinine (mg/dL) 1.26 + 0.36 1.14 + 0.30 1.18 + 0.31 1.19 + 0.32 ,0.001
...............................................................................................................................................................................
a
Other CV death includes all CV deaths not ascribed to pump failure or sudden death; CV, cardiovascular; SBP, systolic blood pressure; BMI, body mass index; HF, heart failure;
CMP, cardiomyopathy; NYHA, New York Heart Association; MI, myocardial infarction; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; ICD,
implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy; LVEF, left ventricular ejection fraction.
(26.5%). Of those who died due to heart failure, 33.2% experienced treatment with LCZ696. Kaplan – Meier curves depicting the time
a hospitalization for heart failure prior to death. Among those who to sudden death and to death from worsening heart failure by treat-
died suddenly, the majority (380, 67.7%) had been last seen alive ment arm are displayed in Figure 1 and Figure 2. Inclusion of the 49
within the hour prior, and 181 (32.3%) had been last seen alive be- patients with presumed sudden deaths and the 66 patients with un-
tween 1 and 24 h. The hazard for both sudden death (HR 0.80, known cause of death in the sudden death definition did not alter
LCZ696 vs.. enalapril, 95% CI 0.68 – 0.94, P ¼ 0.008) and death the apparent treatment benefit of LCZ696 (HR 0.84, 95% CI
due to worsening heart failure (HR 0.79, LCZ696 vs. enalapril, 0.72 –0.97, P ¼ 0.02). Resuscitated sudden deaths, in which the pa-
95% CI 0.64 – 0.98, P ¼ 0.034) was significantly reduced by tient survived, occurred in 16 patients in the LCZ696 arm compared
1994 A.S. Desai et al.
Table 3 Adjudicated causes of death and rates of death by cause according to treatment assignment, PARADIGM-HF
(N 5 8399)
with 28 patients in the enalapril arm (HR 0.57, 95% CI 0.31 – 1.04, nearly identical results to those already described (Supplementary
P ¼ 0.07). When combining both resuscitated and non-resuscitated material online, Figures S1 and S2).
sudden death events, we observed a 22% reduction in the risk of Fatal MI was infrequent, occurring in ,1% of patients, and ac-
sudden death in those treated with LCZ696 compared with enala- counting for 3.7% of all deaths; the observed difference between
pril (HR 0.78, 95% CI 0.66, 0.92, P ¼ 0.002). The magnitude of the treatment arms was similar to that seen in HF death and sudden
treatment effect on sudden death did not differ amongst patients death, but was not statistically significant. Fatal strokes occurred in
with (36 of 561 sudden deaths) and without (525 of 561 sudden ,1% of patients, accounted for 4.1% of all deaths, and did not differ
deaths) an implantable defibrillator (HR in those with an ICD 0.49 between treatment arms. Very few deaths were ascribed to other
(95% CI 0.25 – 0.98); HR in those without an ICD 0.82 (95% CI cardiovascular causes such as pulmonary embolism or cardiovascu-
0.69 – 0.98, interaction P ¼ 0.17). Further sensitivity analyses using lar procedures. Malignancy and infection accounted for over half of
competing risks methods to examine the cumulative incidence of the non-cardiovascular deaths, which did not differ between treat-
sudden death and death due to worsening heart failure produced ment groups (Table 3).
Mode of death in PARADIGM-HF 1995
Understanding the precise mechanism of benefit of LCZ696 in heart assessment of reduction in mortality and morbidity (charm) program. Circulation
2004;110:2180 –2183.
failure may provide important insights into the pathophysiology of
4. Remme WJ, Cleland JG, Erhardt L, Spark P, Torp-Pedersen C, Metra M, Komajda M,
heart failure and should be a priority for future study. Moullet C, Lukas MA, Poole-Wilson P, Di Lenarda A, Swedberg K. Effect of carve-
This analysis should be viewed in the context of its limitations. At- dilol and metoprolol on the mode of death in patients with heart failure. Eur J Heart
Fail 2007;9:1128 –1135.
tribution of cause of death in a clinical trial is based on historical in-
5. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity
formation, which is dependent on the quality of the source and mode of death among survivors of acute myocardial infarction with clinical evi-
documentation available and presumes that such documentation dence of heart failure. A report from the AIRE study investigators. Eur Heart J 1997;
can provide mechanistic insights. Nevertheless, the use of a blinded, 18:41 –51.
6. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.
independent clinical events committee provided consistency The effect of spironolactone on morbidity and mortality in patients with severe
throughout the endpoint review process, and assured that deaths heart failure. Randomized Aldactone Evaluation study investigators. N Engl J Med
would be ascribed similarly in patients from different sites and re- 1999;341:709 –717.
7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe
gions, and in both treatment groups. Attributing causes to death congestive heart failure. N Engl J Med 1987;316:1429 –1435.
in clinical trials is especially challenging in cases of suspected sudden 8. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced
cardiac death, and this classification does not necessarily imply a left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;
325:293 –302.
common pathophysiology. However, in PARADIGM-HF, attribution 9. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R,
of sudden death did require the death to be an unexpected death in Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J,
an apparently stable patient; patients last seen .24 h prior to death Hughes V, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of ena-
lapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive
failure patients with sudden death: results from the assessment of treatment with mortality in chronic heart failure. ATLAS study group. Circulation 1999;100:
lisinopril and survival (ATLAS) trial. Circulation 2000;102:611 –616. 2312 –2318.
22. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, 25. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA,
Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Effects of candesar- Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA. Effects of high-
tan in patients with chronic heart failure and reduced left-ventricular systolic function dose versus low-dose losartan on clinical outcomes in patients with heart failure
intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840 –1848.
trial. Lancet 2003;362:772–776. 26. Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Stockbridge NL,
23. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Targum SL, Temple R; on behalf of the Standardized Data Collection for Cardio-
Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic vascular Trials Initiative. Standardized definitions for cardiovascular and stroke end
heart failure and mild symptoms. N Engl J Med 2011;364:11–21. point events in clinical trials. Draft definitions for CDISC, July 3, 2014. http://www.
24. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, cdisc.org/system/files/all/reference_material/application/pdf/Draft%
Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of 20Definitions%20for%20CDISC%20July%203,%202014.pdf (18 December
the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and 2014).